2008 Announcements

Application to commence US trials of photoprotective afamelanotide First IND lodged at FDA for afamelanotide Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announces the filing of its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its photoprotective first-in-class compound, afamelanotide. The lodgement of the IND signifies a major event in Clinuvel’s history. While the company has advanced its clinical program in Australia, Europe and Switzerland, it now seeks entry into the US. The IND is the first formal step in conducting US clinical trials which will support a marketing application for…

Appendix 3Y - Change in Director's interest

Appendix 3B

2008 CEO AGM Presentation

2008 CSO AGM Presentation

2008 AGM Results of Meeting

Appendix 4C

Notice of Meeting and Proxy form

Financial Report Year Ended 30 June 2008